Palladyne AI Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Palladyne AI Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.25M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $7.79M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $6.15M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $14.57M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.08M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $8.81M | Mar 29, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.25M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $7.79M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $6.15M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $14.57M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.08M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $8.81M | Mar 29, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.04M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($72.62M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($115.59M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($157.13M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($81.51M) | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | ($1.5K) | Mar 31, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($32.40M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($26.92M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($120.96M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($177.04M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($80.99M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($21.00M) | Mar 29, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.90M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $10.44M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $39.01M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $34.14M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $17.52M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $14.12M | Mar 29, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.64M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($22.63M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($76.62M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($65.39M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($42.10M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($16.88M) | Mar 29, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $713.0K | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $265.0K | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $782.0K | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.50M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.69M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $950.0K | Mar 29, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.71M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $56.25M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $60.43M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $167.63M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $235.82M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $38.05M | Mar 29, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.04M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $65.79M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $19.52M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $23.18M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $21.86M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $5.15M | Mar 29, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.68M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($9.53M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $40.91M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $144.45M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $213.96M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $32.91M | Mar 29, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.73M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 5, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($480.79M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($490.83M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($418.21M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($302.62M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($145.49M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($63.98M) | Mar 29, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.22M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $31.19M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $23.14M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $35.16M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $217.11M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $33.66M | Mar 29, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.12M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 33.88M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 25.88M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 25.71M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 137.72M | Mar 16, 2023 |
| FY2022 | Sep 24, 2021 | 21.48M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 104.04M | Mar 29, 2022 |